Article
Predicting MammaPrint Recurrence Risk from Breast Cancer Pathological Images Using a Weakly Supervised Transformer
2025-04-29
Abstract excerpt
Recurrence related to poor prognosis is a leading cause of mortality in patients with breast cancer (BC). The MammaPrint (MP) genomic assay is designed to stratify recurrence risk and evaluate chemotherapy benefits for early-stage HR+/HER2- BC patients. However, MP fails to reveal spatial tumor morphology and is limited by high costs. In this study, we establish a BC MP cohort and develop CPMP, a weakly supervised...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ab5a7b01-807f-5fc4-9eb9-0588521c89b8
- DOI
- 10.1101/2025.04.26.648504
